Abstrait

Nestin: A Biomarker of Aggressive Uterine Cancers

Kathleen M Darcy

Cancers of the uterine corpus are the most common gynecologic cancers in the United States with incidence and mortality increasing both in the United States of America and globally. Most uterine cancers have a favorable prognosis and are cured by surgery alone. Identifying patients at risk of recurrence, particularly those misclassified as low risk by current clinicopathologic standards is of paramount importance. Physicians need better risk stratification tools to identify when and which adjuvant therapy will decrease recurrence. Validated biomarkers with prognostic, predictive, and/or theragnostic value will likely play a vital role in advancing assessments of risk and guiding clinical management decision making.